Omitting GnRH-antagonist Dose on the Day of Ovulation Trigger

Impact of Omitting GnR-antagonist on Ovulation Trigger Day in the Fresh Autologous IVF/ICSI Cycles

Status

UNKNOWN

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03044756

Enrollment

100

Registered

2017-02-07

Start date

2017-01-01

Completion date

2017-12-30

Last updated

2017-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pituitary Downregulation

Keywords

GnRH antagonist, Pituitary downregulation, IVF, ICSI

Brief summary

Omitting the GnRH antagonist on the day of the trigger can be cost effective and more convenient to the women. We will study the impact of omitting the antagonist dose in a prospective randomized trial

Interventions

DRUGOmit Citrotide 0.25 dose on the day of triggering of ovulation

Omit Citrotide 0.25 dose on the day of triggering of ovulation

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Investigator, Outcomes Assessor)

Intervention model description

Randomized controlled study

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 35 Years

Healthy volunteers

Inclusion criteria

* All antagonist cycle ivf who agree to participate

Exclusion criteria

* expected poor responders.

Design outcomes

Primary

Measure	Time frame	Description
Number of retrieved oocytes	One Month	total number and maturation of the retrieved oocytes

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026